Abbott Gmbh & Co Kg

Basf Aktiengesellschaft

Abb Vie Deutschland Gmbh & Co. Kg

Abbott Laboratories Corporation

Abbvie Inc.

Other

Abbvie Deutschland Gmbh and Co Kg

Basf Aktienegesellschaft

Andreas Haupt

Karla Drescher

Liliane Unger

Wilfried Martin Braje

Andreas Kling

Bernd Janssen

Sean Colm Turner

Teresa Barlozzari

Karsten M Wicke

Roland Grandel

Thomas Zierke

Ana Lucia Relo

Wilhelm Amberg

Kurt Ritter

Udo Lange

Gisela Backfisch

Wilfried Lubisch

Ernst Buschmann

Harald Bernard

Hervé Geneste

Frauke Pohlki

Min Zhang

Helmut Mack

Herve Geneste

Anton Bespalov

Wolfgang Wernet

Mario Mezler

Margaretha Henrica Maria Bakker

Viktor Lakics

Matthias Mayrer

Ulrich Karl

Stefan Muller

Ana-Lucia Relo

Juergen Delzer

Barbara Vogg

Hannes Koolman

Marco Thyes

Daryl Richard Sauer

Lothar Janitschke

Jürgen Dinges

Bernd De Potzolli

Christophe Henry

Hans-Guenther Hege

Helmut Lietz

Carolin Hoft

Armin Beyerbach

Martina Ullrich

Robert Van Waterschoot

George R Pettit

Gerd Steiner

Dorothea Starck

Yanbin Lao

Franz Emling

Cynthia A Romerdahl

Jurgen Weymann

Ana Lucia Jongen-Relo

Xiaona Zhao

Daniel Belik

Michael Boretzky

Christian Griesinger

Günter Blaich

Thomas Erhard

Anna Linsenmeier

Raimund Peter

Matthias Kroner

Michael Ochse

Michael D Williams

Werner Seitz

Heinz Hillen

Dagmar Klinge

Astrid Netz

Georg Kettschau

Martin Schmidt

Hans-Jurgen Teschendorf

Subhashis Banerjee

Michael Kluge

Gerhard Keilhauer

Hans-Jörg Treiber

Xiao-Dong Qian

Francisco Javier Garcia-Ladona

Andrea Hager-Wernet, Legal Representative

Kai Blumbach

Stefan M&uuml;ller

Jayaram Kasturi Srirangam

Johann-Christian Zechel

Alfred Hahn, Legal Representative

Kieran P M Durkin

Jincheng Wang

Lynette Smyth

Hervè Geneste

John Darbyshire

Dietmar Schöbel

Jurgen Weyman

Scott Mittelstadt

Hans-Jürgen Teschendorf

Ruxu Xu

Bernd Riedl

Helmut Griesser

Ulrich Schmidt

Gerhard Haas

The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HTreceptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HTreceptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HTreceptor.

[object Object]

The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HTreceptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HTreceptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HTreceptor.

Tricyclic quinoline and quinoxaline derivatives

The present invention relates to compound of formula (I) as tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, useful for modulating the 5-HTreceptor and preventing and/or treating conditions and disorders that respond to the modulation of the 5-HTreceptor. The present invention also relates to methods for producing compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for preventing or treating conditions and disorders that respond to the modulation of the 5-HTreceptor by administering compounds of formula (1) or pharmaceutical compositions thereof.

Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators

The present invention relates to tricyclic hexahydrodiazepinoquinolines, such as compounds of formula (I), carrying a substituted alkyl radical, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HTreceptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HTreceptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HTreceptor, and processes for preparing such compounds and compositions. 

Hexahydrodiazepinoquinolines carrying a substituted alkyl radical

The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. In formula I, the variables have the following meanings:

Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor

The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor.

The present invention relates to aromatic compounds of the formula I wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Rand wherein Ar may also carry 1 or 2 radicals R; The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor

The invention relates to 5-ring heteroaromatic compounds of general formula (I), their use for the treatment and/or prevention of diseases, and medicaments containing same.

5-ring heteroaromatic compounds and their use as binding partners for 5-HT5 receptors

The present invention relates to benzenesulfonyl or sulfonamide compounds of formulae IA and IB wherein the variables have the meanings given in the claims and the description, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HTreceptor.

The present invention relates to N-Phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds of formula I wherein the variables have the meanings given in the claims and the description, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HTreceptor.

The invention relates to compounds of the formula (I) wherein the variables have meanings given in the claims and the description. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a 5HTreceptor ligand. 

Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor

The present invention relates to compounds of formula (I) wherein A is C-C-alkyl, C-C-haloalkyl, C-C-hydroxyalkyl, C-C-alkenyl, C-C-halo-alkenyl, C-C-cycloalkyl, aryl-C-C-alkyl, aryl-C-C-alkenyl, aryl or hetaryl;is a single or double bond; Xand Xare N, CR, NRor CRR; R, Rand Rare H, halogen, CN, NO, C-C-alkyl, C-C-alkoxy, C-C-alkylcarbonyl, etc. or two geminal radicals Rand Rtogether with the carbon atom to which they are bound may form a carbonyl group or a 3- to 6-membered carbocyclic or heterocyclic spiro-annulated ring; Ris hydrogen, C-C-alkyl, C-C-alkylcarbonyl, C-C-haloalkyl, etc.; or two vicinal radicals R, R, Ror Rtogether with Xand Xform a five- or six-membered carbocyclic or heterocyclic fused ring; Y, Yand Yare N or CR; Ris H, halogen, CN, NO, C-C-alkyl, C-C-alkoxy, C-C-alkylcarbonyl, C-C-haloalkyl, etc.; wherein a maximum of 3 of the radicals X, X, Y, Yand Yare selected from NRand N; Ris hydrogen, C-C-alkyl, C-C-hydroxyalkyl, C-C-haloalkyl, etc.; Ris C-C-alkyl or C-C-haloalkyl; n is 0, 1 or 2; physiologically tolerated acid addition salts and the N-oxides thereof, pharmaceutical composition comprising them, a method for treating medical disorders selected from diseases of the central nervous system, addiction diseases or obesity, said method comprising administering an effective amount of such compounds to a subject in need and the use of such a compound for preparing a pharmaceutical compositions.

Growing community of inventors

Schwetzingen, Germany

Andreas Haupt